TAG:
Thermo Fisher Scientific
Astorg Makes Billion-Dollar Bet on Microbiology Testing
By Janette Wider | From the Volume XXXIII, No. 7 – May 26, 2026 Issue
Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to …
Digital Pathology’s Next Wave May Be in Precision Medicine
By Scott Wallask | From the Volume XXXIII, No. 5 – April 13, 2026 Issue
We’ve noted before that the adoption of digital pathology has not been as swift or strong as originally predicted. Many factors contribute to that concern. This topic came up in a recent interview The Dark Report conducted with Imoge…
Global IVD Woes in China Should Resonate with US Labs
By Mark Terry | From the Volume XXXIII, No. 3 – March 2, 2026 Issue
In vitro diagnostics (IVD) companies reported a mix of overall growth, with many noting continuing challenges in their diagnostics divisions for recent quarterly financial results. Thermo Fisher Scientific, QuidelOrtho, and Danaher reported the…
Cuts to Rural Labs Boost RESULTS Act Support
By Scott Wallask | From the Volume XXXIII, No. 1 – January 19, 2026 Issue
CEO SUMMARY: Two related legislative concerns should have the sharp attention of clinical laboratory leaders, particularly those in rural areas. On one end, PAMA cuts are scheduled to hit on Jan. 31 short of another reprieve from Congress. Meanwhile, lawmakers at a recent …
Reforms in China Affect IVD Companies’ Q3 2025 Earnings
By Mark Terry | From the Volume XXXII, No. 16 – November 17, 2025 Issue
Most of the in vitro diagnostics (IVD) manufacturers that serve clinical laboratories worldwide reported facing financial “headwinds” in the China IVD market that affected their third-quarter performance. This was due to policy changes in the country…
2025 Ranking of the World’s Top 13 IVD Corporations
By Mark Terry | From the Volume XXXII, No. 13 – September 15, 2025 Issue
BASED ON PUBLICLY-REPORTED 2024 DIAGNOSTICS-RELATED REVENUE, four in vitro diagnostics (IVD) companies continue to dominate the global market, as they have for the last two years: Thermo Fisher Scientific, Roche, Danaher, and Abbott Laboratories. The top 13 companies …
Despite Trade Tariffs, IVD Firms Report Upbeat Earnings
By Mark Terry | From the Volume XXXII, No. 12 – August 25, 2025 Issue
LEADING IN VITRO DIAGNOSTICS (IVD) COMPANIES RECENTLY REPORTED POSITIVE QUARTERLY FINANCIALS despite swirling concerns about trade tariffs and cuts to US federal research grants. It’s not yet clear what the long-term effect of tariffs’ will be on IVD manu…
Fast, $17.5B Deal Lands Waters Corp. in IVD Market
By Janette Wider | From the Volume XXXII, No. 11 – August 4, 2025 Issue
WHEN BECTON DICKINSON (BD) ANNOUNCED ITS INTENT to spin off its in vitro diagnostics (IVD) and life sciences units in February, few observers expected a deal to close just five months later. But now that such an agreement has occurred as of July 14, the buy…
June 23, 2025, Intelligence: Late-Breaking Lab News
By Scott Wallask | From the Volume XXXII, No. 9 – June 23, 2025 Issue
Clinical labs that have business in clinical trials involving genetic samples should note that on June 18, the Food and Drug Administration (FDA) ordered a review of new trials that send samples to “hostile countries for genetic engineering.” The FDA mentioned China specifically. Th…
May 12, 2025, Intelligence: Late-Breaking Lab News
By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue
Yet another clinical laboratory has sold off part of its services to a national commercial lab. Labcorp announced on April 21 that it had finalized its acquisition of North Mississippi Health Services’ (NMHS) ambulatory outreach laboratory business. A…
CURRENT ISSUE
Volume XXXIII, No. 7 – May 26, 2026
Momentum is building on Capitol Hill to pass the RESULTS Act, which would stave off drastic 15% reimbursement cuts under PAMA. Advocates seek lobbying help from clinical labs and anatomic pathology practices. Also, The Dark Report examines Roche’s deal to acquire PathAI.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized